metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)
versus trastuzumab
	pertuzumab plus trastuzumab vs. trastuzumab	1	-	-1395 [-2552; -239] /10000 74/129 vs. 92/129	-
versus trastuzumab plus chemotherapy
	trastuzumab plus endocrine therapy vs. trastuzumab plus chemotherapy	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
versus trastuzumab plus docetaxel
	pertuzumab plus trastuzumab plus docetaxel vs. trastuzumab plus docetaxel	2	-982 [-1627; -337] /10000 113/402 vs. 154/406	-1078 [-2333; 177] /10000 57/119 vs. 71/121	-
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus lapatinib plus capecitabine
	neratinib plus capecitabine vs. lapatinib plus capecitabine	2	-569 [-1868; 730] /10000 43/51 vs. 45/50	-933 [-2687; 820] /10000 34/51 vs. 38/50	-
versus placebo
	neratinib vs. placebo	1	-	-	-
versus trastuzumab plus capecitabine
	tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine	2	-1037 [-1854; -221] /10000 130/410 vs. 85/202	-500 [-1432; 432] /10000 178/320 vs. 97/160	-